What Бикалутамид Treats: Main Uses and Benefits

This medication is primarily used to help manage prostate cancer that may have spread to other parts of the body (metastatic), addressing the condition where symptomatic discomfort is linked to prostate tissue growth. It is often administered as part of a therapeutic regimen, alongside other treatments.

The treatment may assist in managing the speed of disease progression and supports management of hormone-sensitive prostate tissue. It helps to manage symptoms that arise from the condition's progression, such as difficulties with urination or general discomfort caused by the presence of the disease. The treatment is commonly used across conditions involving episodic or fluctuating manifestations.

---

Quick Fact: Relief for Urinary Symptoms The drug is relevant in clinical settings that involve sustained symptomatic support, helping to ease the overall burden of distressing physical manifestations. This may assist in easing the overall symptom load and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility Rules for Bicalutamide

Bicalutamide is officially approved for use exclusively in adult males. This eligibility is derived from the drug's intended purpose as an antiandrogen for hormone-dependent conditions. The official labeling specifies several populations for whom use is contraindicated (absolutely prohibited).

Category	Official Regulatory Wording
Contraindicated Populations	Females (all ages); Pregnancy and Lactation; Patients with known hypersensitivity to bicalutamide or its excipients.
Conditional Use / Caution	Patients with severe hepatic impairment; Patients with certain pre-existing cardiac risk factors (due to risk of QTc prolongation).

Use in the pediatric population (children and adolescents) is not recommended or not established by regulatory authorities due to the nature of the primary indication. For the geriatric population (older adults), no specific dose adjustment is typically required based on age alone. While mild renal impairment does not necessitate a dose adjustment, use in patients with severe hepatic impairment must proceed with caution and requires monitoring, as elimination of the drug may be delayed.

The interaction profile for Bicalutamide is defined by its inhibitory effect on the CYP 3A4 enzyme and potential for pharmacodynamic synergy, as documented in official regulatory labeling.

Classification	Interacting Agents / Conditions	Regulatory Constraint
Contraindicated	Terfenadine, Astemizole, Cisapride	Explicitly prohibited due to interaction risk.
Metabolic Risk	Cimetidine, Ketoconazole	Caution; these may increase Bicalutamide plasma concentrations by inhibiting drug oxidation.
Exposure Alteration	Coumarin Anticoagulants (e.g., Warfarin)	Requires close monitoring of Prothrombin Time (PT) and International Normalized Ratio (INR).
Pharmacodynamic Risk	QT-prolonging agents (e.g., Class IA/III Antiarrhythmics)	Caution is advised due to potential additive effect on QT interval prolongation.

The drug's active enantiomer is officially identified as an inhibitor of CYP 3A4, which leads to necessary precautions with co-administered drugs metabolized by this enzyme, including cyclosporin and certain calcium channel blockers. Specific monitoring of blood glucose is advised when Bicalutamide is used in combination with LHRH agonists, related to an observed reduction in glucose tolerance. In terms of patient-specific cautions, regulatory documents advise using the product with caution in patients with moderate to severe hepatic impairment, due to the risk of slower clearance and increased drug accumulation. No clinically significant interaction has been documented between Bicalutamide and food.

Бикалутамид acts as a selective, competitive, non-steroidal antagonist of the androgen receptor (AR), the primary biological target of endogenous androgens like testosterone and dihydrotestosterone (DHT). The active component, the R-enantiomer, binds to the ligand-binding domain of the intracellular AR in androgen-responsive target tissues.

Binding of R-bicalutamide competitively inhibits the association of natural androgens with the receptor, thus preventing the formation of the activated androgen-receptor complex. This antagonism blocks the subsequent nuclear translocation of the AR complex, which is required for transcriptional activity. Consequently, the drug impairs the binding of the receptor to the Androgen Response Elements (AREs) in the target gene promoters, inhibiting the recruitment of coactivator proteins and suppressing the transcription of androgen-responsive genes. This intracellular cascade results in a systemic modulation of androgen signaling by blocking receptor-mediated actions across various tissues.

How to Use Bicalutamide: Official Administration Guidelines

Bicalutamide is administered via the oral route as a film-coated tablet, following a standardized approach. It is intended for long-term continuous administration for the duration specified in the treatment plan.

---

Official Dosing and Schedule

Bicalutamide is taken once daily at approximately the same time each day to maintain consistent drug levels. The dose is determined by the specific context of use. Two primary doses are utilized:

Usage Context	Standard Daily Dose
Combination Therapy	50 mg once daily
Monotherapy/Adjuvant Use (Regionally approved)	150 mg once daily

---

Administration Requirements

The tablet should be swallowed whole with water and must not be crushed or chewed. Intake is flexible and permitted with or without food. When used in combination with another hormonal agent (LHRH analog), Bicalutamide administration is typically started either concurrently with or shortly before the combined therapy.

Missed Dose Rule: If a dose is missed, the patient should skip the missed dose and take the next dose at the scheduled time; a double dose should not be taken.

Population-Specific Dosing

No dosage adjustment is necessary for older adults or patients with mild to moderate renal impairment. However, caution and monitoring are advised in patients with severe hepatic impairment, as drug clearance may be altered in this population.

Research evidence / Overview of studies for Бикалутамид

Evidence for Use in Locally Advanced Prostate Cancer (Non-Metastatic)

The research examined Bicalutamide for locally advanced prostate cancer was based on large-scale, long-term Randomized Controlled Trials (RCTs). These studies were designed to compare Bicalutamide against a placebo in men with localized or locally advanced disease. Researchers monitored key outcomes such as Time to Objective Progression (PFS) and Overall Survival (OS). Research examined Bicalutamide in addition to established treatments (such as radiotherapy or surgery), or as a monotherapy alongside clinical monitoring (watchful waiting).

Studies focusing on patients with locally advanced disease reported how symptoms evolved in the observed populations, as measured by Time to Objective Progression when compared to the placebo group. The evidence for this indication is broadly classified as High. However, when final analyses across the full study population were reported, data show patterns related to Overall Survival that were generally similar between the Bicalutamide group and the placebo group.

Evidence for Use in Advanced and Metastatic Prostate Cancer

Bicalutamide was evaluated in studies for advanced or metastatic prostate cancer, typically as part of Combined Androgen Blockade (CAB) with an LHRH agonist. The research examined involved RCTs and subsequent Meta-analyses that synthesized data from multiple trials. These studies primarily monitored Overall Survival (OS), along with time-based outcomes such as the Time to Disease Progression.

The trials and subsequent meta-analyses reported measurements of these outcomes in patients receiving the combined approach versus those receiving monotherapy. The evidence for this indication is generally classified as Moderate. Comparative evidence is limited, and scientific literature notes that the findings about the measured outcomes were mixed across the systematic reviews that examined this question.

What Is Still Uncertain About Bicalutamide's Research Base

One key area of uncertainty is the question of long-term Overall Survival across the entire patient population with locally advanced disease, as the large trials did not establish a clear difference compared to placebo. Comparative evidence against other newer hormonal agents for these indications remains limited. The results apply only to the populations studied, and subgroup findings in some areas are uncertain, such as the data for Bicalutamide monotherapy observed in men with only localized, early-stage disease.

Common questions about Бикалутамид (FAQ)

Q: What is the best time of day to take Бикалутамид?

Бикалутамид is typically taken once daily. The prescribing information indicates it is usually taken with or without food, with the specific time and dosage determined by your healthcare provider. Dosing should follow the specific instructions provided by your healthcare professional. Starting at a lower dose, as directed by a healthcare provider, can help manage potential side effects.

Q: Can I stop taking Бикалутамид suddenly if I feel better?

Stopping this medication suddenly is generally not recommended, even if symptoms improve significantly. Stopping abruptly may lead to discontinuation symptoms, which can include dizziness and mood changes. Always consult with your healthcare provider to establish a specific tapering schedule, if needed, to minimize these potential effects.

Q: Is Бикалутамид safe to use long-term?

Бикалутамид is generally considered an option for long-term use in managing the prescribed condition. Long-term safety is monitored through ongoing studies and clinical experience. Long-term use may require regular follow-up appointments and monitoring by a healthcare professional, as determined by your treatment plan. Long-term use is associated with managing symptoms for many patients, but individual results may vary.

How to Store and Dispose of Bicalutamide

Official regulatory documents define strict conditions for the storage and disposal of bicalutamide tablets.

---

Storage Requirements

Bicalutamide must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be protected from degradation by keeping it in a closed container away from heat, moisture, and direct light.

• Temperature: Controlled Room Temperature (20 C to 25 C).
• Protection: Keep in a closed container, away from heat and moisture.
• Child Safety: The product must be kept out of the reach of children.

---

Disposal Instructions

Unused or expired bicalutamide should not be thrown away via wastewater or household waste. Disposal of the unused medicinal product or any waste material must be carried out in accordance with local regulatory requirements.